List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2710997/publications.pdf Version: 2024-02-01



Кошсні Тамира

#	Article	IF	CITATIONS
1	Association of achieved blood pressure after treatment for primary aldosteronism with long-term kidney function. Journal of Human Hypertension, 2022, 36, 904-910.	2.2	4
2	Clinical usefulness of left ventricular outflow tract velocity time integral for heart failure with reduced ejection fraction with rapid atrial fibrillation during landiolol treatment. Journal of Cardiology, 2022, 79, 21-29.	1.9	1
3	Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. Hypertension Research, 2022, 45, 221-231.	2.7	61
4	ATRAP, a receptor-interacting modulator of kidney physiology, as a novel player in blood pressure and beyond. Hypertension Research, 2022, 45, 32-39.	2.7	9
5	Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis. Clinical Rheumatology, 2022, 41, 911-919.	2.2	20
6	Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. Diabetes Research and Clinical Practice, 2022, 185, 109231.	2.8	4
7	GPR143, a L-DOPA receptor, induced migration and proliferation of vascular smooth muscle cells is involved in monocrotaline-induced pulmonary hypertension in rats. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2022, 95, 1-YIA-06.	0.0	0
8	Impact of atrial fibrillation and the clinical outcomes in patients with acute myocardial infarction from the K-ACTIVE registry. Journal of Cardiology, 2022, 79, 768-775.	1.9	5
9	The reappearance of de Winter's pattern caused by acute stent thrombosis: A case report. Journal of Cardiology Cases, 2022, , .	0.5	0
10	Deficiency of the kidney tubular angiotensin II type1 receptor–associated protein ATRAP exacerbates streptozotocin-induced diabetic glomerular injury via reducing protective macrophage polarization. Kidney International, 2022, 101, 912-928.	5.2	8
11	Cardiac involvement in coronavirus disease 2019 assessed by cardiac magnetic resonance imaging: a meta-analysis. Heart and Vessels, 2022, 37, 1570-1582.	1.2	6
12	Blood Pressure Elevation of Tubular Specific (P)RR Transgenic Mice and Lethal Tubular Degeneration due to Possible Intracellular Interactions between (P)RR and Alternative Renin Products. International Journal of Molecular Sciences, 2022, 23, 302.	4.1	5
13	Successful implantation of left ventricular lead for a cardiac resynchronization therapy defibrillator through a persistent left superior vena cava using the anchor balloon technique. Journal of Cardiology Cases, 2022, 25, 308-311.	0.5	4
14	Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocrine Journal, 2022, 69, 327-359.	1.6	67
15	Native T1 heterogeneity for predicting reverse remodeling in patients with non-ischemic dilated cardiomyopathy. Heart and Vessels, 2022, 37, 1541-1550.	1.2	7
16	Possible clinical usefulness of polygenic risk scores among patients with established atherosclerotic cardiovascular disease. Atherosclerosis, 2022, , .	0.8	0
17	SARS-CoV-2 spike protein antibody titers 6Âmonths after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan. Clinical and Experimental Nephrology, 2022, 26, 988-996.	1.6	6
18	Association of cardiovascular disease risk and changes in renin levels by mineralocorticoid receptor antagonists in patients with primary aldosteronism. Hypertension Research, 2022, 45, 1476-1485.	2.7	8

#	Article	IF	CITATIONS
19	Blood pressure after treatment with sodium–glucose cotransporterÂ2 inhibitors influences renal composite outcome: Analysis using propensity scoreâ€matched models. Journal of Diabetes Investigation, 2021, 12, 74-81.	2.4	8
20	Impairment of right ventricular strain evaluated by cardiovascular magnetic resonance feature tracking in patients with interstitial lung disease. International Journal of Cardiovascular Imaging, 2021, 37, 1073-1083.	1.5	2
21	Clinical impact of admission urinary 8-hydroxydeoxyguanosine level for predicting cardiovascular mortality in patients with acute coronary syndrome. Heart and Vessels, 2021, 36, 38-47.	1.2	6
22	Diagnostic performance and limitation of quantitative flow ratio for functional assessment of intermediate coronary stenosis. Journal of Cardiology, 2021, 77, 492-499.	1.9	7
23	May need more comprehensive approach to residual risks in well controlled hypertensive patients. Hypertension Research, 2021, 44, 253-255.	2.7	0
24	Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium–Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Diabetes Technology and Therapeutics, 2021, 23, 110-119.	4.4	11
25	Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease. Scientific Reports, 2021, 11, 951.	3.3	4
26	Impaired coronary flow reserve evaluated by phase-contrast cine magnetic resonance imaging in patients with atrial fibrillations. Heart and Vessels, 2021, 36, 775-781.	1.2	3
27	Sex Differences in Renal Outcomes After Medical Treatment for Bilateral Primary Aldosteronism. Hypertension, 2021, 77, 537-545.	2.7	8
28	Sodium–glucose cotransporterÂ2 inhibitorâ€induced reduction in the mean arterial pressure improved renal composite outcomes in typeÂ2 diabetes mellitus patients with chronic kidney disease: A propensity scoreâ€matched model analysis in Japan. Journal of Diabetes Investigation, 2021, 12, 1408-1416.	2.4	9
29	Extracellular volume fraction by T1 mapping predicts improvement of left ventricular ejection fraction after catheter ablation in patients with non-ischemic dilated cardiomyopathy and atrial fibrillation. International Journal of Cardiovascular Imaging, 2021, 37, 2535-2543.	1.5	2
30	Characteristics and Prognosis of Patients with Vasospastic Angina Diagnosed by a Provocation Test with Secondary Prevention Implantable Cardioverter Defibrillator. International Heart Journal, 2021, 62, 224-229.	1.0	4
31	Acute Myocarditis by Immune Checkpoint Inhibitor Identified by Quantitative Pixel-Wise Analysis of Native T1 Mapping. Circulation: Cardiovascular Imaging, 2021, 14, e012177.	2.6	1
32	Association of aldosterone and blood pressure with the risk for cardiovascular events after treatments in primary aldosteronism. Atherosclerosis, 2021, 324, 84-90.	0.8	10
33	Prognostic impact of muscle and fat mass in patients with heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 568-576.	7.3	39
34	Subtype-specific trends in the clinical picture of primary aldosteronism over a 13-year period. Journal of Hypertension, 2021, Publish Ahead of Print, 2325-2332.	0.5	2
35	The Types and Proportions of Commensal Microbiota Have a Predictive Value in Coronary Heart Disease. Journal of Clinical Medicine, 2021, 10, 3120.	2.4	8
36	Efficacy of the Self-management Support System DialBetesPlus for Diabetic Kidney Disease: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2021, 10, e31061.	1.0	6

#	Article	IF	CITATIONS
37	Tissue-specific expression of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2, in mouse models of chronic kidney disease. Scientific Reports, 2021, 11, 16843.	3.3	7
38	Impact of sarcopenic obesity on long-term clinical outcomes after ST-segment elevation myocardial infarction. Atherosclerosis, 2021, 335, 135-141.	0.8	4
39	Prologue: Special Spotlight Issue on Japan. Journal of Human Hypertension, 2021, , .	2.2	1
40	A case of a coronary covered stent for repeated restenosis at the anastomosis site between saphenous vein graft and graft prosthesis. Journal of Cardiology Cases, 2021, 25, 110-114.	0.5	2
41	Prognostic value of resting coronary sinus flow determined by phase-contrast cine cardiovascular magnetic resonance in patients with known or suspected coronary artery disease. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 97.	3.3	12
42	The evaluation of noninferiority for renal composite outcomes between sodium–glucose cotransporter inhibitors in Japan. Primary Care Diabetes, 2021, 15, 1058-1062.	1.8	2
43	Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database. Diabetes Care, 2021, 44, 2542-2551.	8.6	42
44	The impact of pre-hospital 12-lead electrocardiogram and first contact by cardiologist in patients with ST-elevation myocardial infarction in Kanagawa, Japan. Journal of Cardiology, 2021, 78, 183-192.	1.9	7
45	Global Strain Measured by Three-Dimensional Speckle Tracking Echocardiography Is a Useful Predictor for 10-Year Prognosis After a First ST-Elevation Acute Myocardial Infarction. Circulation Journal, 2021, 85, 1735-1743.	1.6	8
46	Coronary artery disease and heart failure in patients with idiopathic pulmonary fibrosis. Heart and Vessels, 2021, 36, 1151-1158.	1.2	6
47	Cardiovascular magnetic resonance assessment of coronary flow reserve improves risk stratification in heart failure with preserved ejection fraction. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 112.	3.3	19
48	Direct Oral Anticoagulant Therapy for Isolated Distal Deep Vein Thrombosis Associated with Cancer in Routine Clinical Practice. Journal of Clinical Medicine, 2021, 10, 4648.	2.4	1
49	An interesting link between quality of sleep and a measure of blood pressure variability. Journal of Clinical Hypertension, 2021, 23, 331-333.	2.0	2
50	Rationale and Design of the Orencia Atherosclerosis and Rheumatoid Arthritis Study (ORACLE) Tj ETQq0 0 0 rgB ⁻ Complications, Subclinical Atherosclerosis. Methods and Protocols, 2021, 4, 83.	[/Overlocl 2.0	۱0 Tf 50 22 0
51	Right ventricular overloading is attenuated in monocrotaline-induced pulmonary hypertension model rats with a disrupted Gpr143 gene, the gene that encodes the 3,4-L-dihydroxyphenyalanine (L-DOPA) receptor. Journal of Pharmacological Sciences, 2021, 148, 214-220.	2.5	4
52	Effects of tumor necrosis factor-α inhibition on kidney fibrosis and inflammation in a mouse model of aristolochic acid nephropathy. Scientific Reports, 2021, 11, 23587.	3.3	27
53	Impact of population density on mortality in patients hospitalized for heart failure – JROAD-DPC Registry Analysis –. Journal of Cardiology, 2020, 75, 447-453.	1.9	8
54	Ubiquinol Improves Endothelial Function in Patients with Heart Failure with Reduced Ejection Fraction: A Single-Center, Randomized Double-Blind Placebo-Controlled Crossover Pilot Study. American Journal of Cardiovascular Drugs, 2020, 20, 363-372.	2.2	17

#	Article	IF	CITATIONS
55	Intravascular ultrasound radiofrequency signal analysis of blood speckles: Physiological assessment of intermediate coronary artery stenosis. Catheterization and Cardiovascular Interventions, 2020, 96, E155-E164.	1.7	3
56	Preliminary Report: The Relevance of Tumor Necrosis Factor-α in Acquired Primary Lymphedema—A Histopathological Investigation. Lymphatic Research and Biology, 2020, 18, 232-238.	1.1	3
57	The influence of longâ€ŧerm administration of SGLT2 inhibitors on blood pressure at the office and at home in patients with type 2 diabetes mellitus and chronic kidney disease. Journal of Clinical Hypertension, 2020, 22, 2306-2314.	2.0	5
58	Relationship between the cardiac magnetic resonance derived extracellular volume fraction and feature tracking myocardial strain in patients with non-ischemic dilated cardiomyopathy. Magnetic Resonance Imaging, 2020, 74, 14-20.	1.8	8
59	Incremental prognostic value of coronary flow reserve determined by phase-contrast cine cardiovascular magnetic resonance of the coronary sinus in patients with diabetes mellitus. Journal of Cardiovascular Magnetic Resonance, 2020, 22, 73.	3.3	16
60	Effects of Erythropoietin-Stimulating Agents on Blood Pressure in Patients with Non-Dialysis CKD and Renal Anemia. Kidney Diseases (Basel, Switzerland), 2020, 6, 299-308.	2.5	3
61	Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS ONE, 2020, 15, e0236132.	2.5	46
62	Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. Hypertension Research, 2020, 43, 1028-1046.	2.7	131
63	Gut microbiota and atherosclerosis: role of B cell for atherosclerosis focusing on the gut-immune-B2 cell axis. Journal of Molecular Medicine, 2020, 98, 1235-1244.	3.9	12
64	Associations Between Changes in Plasma Renin Activity and Aldosterone Concentrations and Changes in Kidney Function After Treatment for Primary Aldosteronism. Kidney International Reports, 2020, 5, 1291-1297.	0.8	14
65	Renin–angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study. Hypertension Research, 2020, 43, 1257-1266.	2.7	43
66	Afternoon blood pressure increase on home blood pressure measurement: A forgotten entity?. Journal of Clinical Hypertension, 2020, 22, 2202-2203.	2.0	1
67	Combination of extracellular volume fraction by cardiac magnetic resonance imaging and QRS duration for the risk stratification for patients with non-ischemic dilated cardiomyopathy. Heart and Vessels, 2020, 35, 1439-1445.	1.2	2
68	Decreased Appendicular Skeletal Muscle Mass is Associated with Poor Outcomes after ST-Segment Elevation Myocardial Infarction. Journal of Atherosclerosis and Thrombosis, 2020, 27, 1278-1287.	2.0	23
69	Baseline Plasma Aldosterone Level and Renin Activity Allowing Omission of Confirmatory Testing in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1990-e1998.	3.6	7
70	Platelet-Derived Thrombogenicity Measured by Total Thrombus-Formation Analysis System in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation Journal, 2020, 84, 975-984.	1.6	5
71	Systematic Review of the Association Between Worsening Renal Function and Mortality in Patients With Acute Decompensated Heart Failure. Kidney International Reports, 2020, 5, 1486-1494.	0.8	13
72	Mass clinical survey as a possible population strategy for the better control of hypertension in Japan. Hypertension Research, 2020, 43, 463-465.	2.7	1

#	Article	IF	CITATIONS
73	Coronary arteritis: a case series. European Heart Journal - Case Reports, 2020, 4, 1-6.	0.6	6
74	Recent Research Advances in Renin-Angiotensin-Aldosterone System Receptors. Current Hypertension Reports, 2020, 22, 22.	3.5	42
75	Basal Plasma Aldosterone Concentration Predicts Therapeutic Outcomes in Primary Aldosteronism. Journal of the Endocrine Society, 2020, 4, bvaa011.	0.2	9
76	Impact of serum lipoprotein (a) level on coronary plaque progression and cardiovascular events in statin-treated patients with acute coronary syndrome: a yokohama-acs substudy. Journal of Cardiology, 2020, 76, 66-72.	1.9	6
77	Prognostic role of bronchial asthma in patients with heart failure. Heart and Vessels, 2020, 35, 808-816.	1.2	6
78	Reactive fibrosis precedes doxorubicinâ€induced heart failure through sterile inflammation. ESC Heart Failure, 2020, 7, 588-603.	3.1	41
79	Effects of Rikkunshito treatment on renal fibrosis/inflammation and body weight reduction in a unilateral ureteral obstruction model in mice. Scientific Reports, 2020, 10, 1782.	3.3	9
80	J-CKD-DB: a nationwide multicentre electronic health record-based chronic kidney disease database in Japan. Scientific Reports, 2020, 10, 7351.	3.3	37
81	Obesity predicts persistence of resistant hypertension after surgery in patients with primary aldosteronism. Clinical Endocrinology, 2020, 93, 229-237.	2.4	7
82	Nadir Aldosterone Levels After Confirmatory Tests Are Correlated With Left Ventricular Hypertrophy in Primary Aldosteronism. Hypertension, 2020, 75, 1475-1482.	2.7	17
83	Diabetes Mellitus Itself Increases Cardio-Cerebrovascular Risk and Renal Complications in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2531-e2537.	3.6	9
84	Association between abdominal fat distribution and coronary plaque instability in patients with acute coronary syndrome. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1169-1178.	2.6	6
85	Direct Oral Anticoagulant Therapy for Cancer-Associated Venous Thromboembolism in Routine Clinical Practice. Circulation Journal, 2020, 84, 1330-1338.	1.6	9
86	Prognostic Significance of a Combination of QRS Score and E/e′ Obtained 2 Weeks After the Onset of ST-Elevation Myocardial Infarction. Circulation Journal, 2020, 84, 1965-1973.	1.6	6
87	Prevalences of hyperuricemia and electrolyte abnormalities in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS ONE, 2020, 15, e0240402.	2.5	17
88	Effect of cosyntropin during adrenal venous sampling on subtype of primary aldosteronism: analysis of surgical outcome. European Journal of Endocrinology, 2020, 182, 265-273.	3.7	11
89	Effect of renin-angiotensin system blockers on contrast-induced acute kidney injury in patients with normal or mild-to-moderate reduced kidney function undergoing coronary angiography: AÂsystematic review and meta-analysis. Clinical Nephrology, 2020, 94, 227-236.	0.7	2
90	GPR143, a L-DOPA receptor, is involved in monocrotaline-induced pulmonary hypertension in rats. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2020, 93, 1-YIA-23.	0.0	0

#	Article	IF	CITATIONS
91	Successful prediction of clinical outcomes using arterial velocity pulse index, a new non-invasive vascular index, in Japan. Vascular Failure, 2020, 3, 43-50.	0.2	1
92	The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertension Research, 2019, 42, 1235-1481.	2.7	1,047
93	Possible interesting link between dipping status and morning surge for subclinical target organ damage in hypertension. Journal of Clinical Hypertension, 2019, 21, 1295-1297.	2.0	1
94	Lateralizing Asymmetry of Adrenal Imaging and Adrenal Vein Sampling in Patients With Primary Aldosteronism. Journal of the Endocrine Society, 2019, 3, 1393-1402.	0.2	10
95	Coronary Flow Reserve by CardiacÂMagnetic Resonance Imaging inÂPatients With Diabetes Mellitus. JACC: Cardiovascular Imaging, 2019, 12, 2579-2580.	5.3	9
96	Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study). Cardiovascular Diabetology, 2019, 18, 110.	6.8	27
97	Doxorubicin induces trans-differentiation and MMP1 expression in cardiac fibroblasts via cell death-independent pathways. PLoS ONE, 2019, 14, e0221940.	2.5	28
98	JSH Statement: Kyoto declaration on hypertension research in Asia. Hypertension Research, 2019, 42, 759-760.	2.7	6
99	An Emerging Role of the Angiotensin Receptor Binding Protein ATRAP as a Possible Novel Player in the Pathophysiology of Visceral Obesity and Metabolic Disorders. , 2019, , 189-209.		0
100	Lubiprostone as a potential therapeutic agent to improve intestinal permeability and prevent the development of atherosclerosis in apolipoprotein E-deficient mice. PLoS ONE, 2019, 14, e0218096.	2.5	20
101	Sex Difference in the Association Between Subtype Distribution and Age at Diagnosis in Patients With Primary Aldosteronism. Hypertension, 2019, 74, 368-374.	2.7	26
102	Effects of rikkunshito on renal fibrosis and inflammation in angiotensin II-infused mice. Scientific Reports, 2019, 9, 6201.	3.3	17
103	<p>Association of endothelial function with thin-cap fibroatheroma as assessed by optical coherence tomography in patients with acute coronary syndromes</p> . Therapeutics and Clinical Risk Management, 2019, Volume 15, 285-291.	2.0	4
104	Effects of ATRAP in Renal Proximal Tubules on Angiotensinâ€Dependent Hypertension. Journal of the American Heart Association, 2019, 8, e012395.	3.7	9
105	Effects of blood pressure lowering in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis. Hypertension Research, 2019, 42, 504-513.	2.7	15
106	Sex-Related Differences in In-Hospital Mortality in Japanese ST-Elevation Acute Myocardial Infarction Patients Presenting to Hospital in the 24 Hours After Symptom Onset ― Results From K-ACTIVE ―. Circulation Reports, 2019, 1, 313-319.	1.0	3
107	Comparison of anti-inflammatory effects of rivaroxaban vs. dabigatran in patients with non-valvular atrial fibrillation (RIVAL-AF study): multicenter randomized study. Heart and Vessels, 2019, 34, 1002-1013.	1.2	14
108	Comparison between instantaneous wave-free ratio versus morphometric assessments by intracoronary imaging. Heart and Vessels, 2019, 34, 926-935.	1.2	6

#	Article	IF	CITATIONS
109	Possible interesting link between Janus kinase 2 mutation and renovascular hypertension. Journal of Clinical Hypertension, 2018, 20, 805-806.	2.0	3
110	Angiotensin II Type 1 Receptor-associated Protein Inhibits Angiotensin II-induced Insulin Resistance with Suppression of Oxidative Stress in Skeletal Muscle Tissue. Scientific Reports, 2018, 8, 2846.	3.3	17
111	Angiotensin receptor-binding molecule in leukocytes in association with the systemic and leukocyte inflammatory profile. Atherosclerosis, 2018, 269, 236-244.	0.8	10
112	East Asia may have a better 1â€year survival following an acute heart failure episode compared with Europe: results from an international observational cohort. European Journal of Heart Failure, 2018, 20, 1071-1075.	7.1	13
113	Relationship between sleep-disordered breathing and renal dysfunction in acute coronary syndrome. Journal of Cardiology, 2018, 71, 168-173.	1.9	2
114	Arterial wall hypertrophy is ameliorated by α2-adrenergic receptor antagonist or aliskiren in kidneys of angiotensinogen-knockout mice. Clinical and Experimental Nephrology, 2018, 22, 773-781.	1.6	4
115	Hydrostatic pressure suppresses fibrotic changes via Akt/GSK-3 signaling in human cardiac fibroblasts. Physiological Reports, 2018, 6, e13687.	1.7	15
116	Late gadolinium enhancement on cardiac magnetic resonance imaging is associated with coronary endothelial dysfunction in patients with dilated cardiomyopathy. Heart and Vessels, 2018, 33, 393-402.	1.2	8
117	The effects of anti-hypertensive drugs and the mechanism of hypertension in vascular smooth muscle cell-specific ATP2B1 knockout mice. Hypertension Research, 2018, 41, 80-87.	2.7	16
118	Prediction of mitral regurgitation resolution after coronary bypass graft surgery and cardiac resynchronization therapy by late gadolinium enhancement magnetic resonance imaging: a case report. European Heart Journal - Case Reports, 2018, 2, yty129.	0.6	0
119	Early Enhanced Leucine-Rich <i>α</i> -2-Glycoprotein-1 Expression in Glomerular Endothelial Cells of Type 2 Diabetic Nephropathy Model Mice. BioMed Research International, 2018, 2018, 1-9.	1.9	19
120	The Japanese Society of Hypertension—Digest of plan for the future. Hypertension Research, 2018, 41, 989-990.	2.7	20
121	Reduced secretion of parathyroid hormone and hypocalcemia in systemic heterozygous ATP2B1-null hypertensive mice. Hypertension Research, 2018, 41, 699-707.	2.7	6
122	An interesting cross-talk between the glucagon-like peptide-1 receptor axis and angiotensin receptor pathway for modulation of renal sodium handling in obesity. Hypertension Research, 2018, 41, 784-786.	2.7	1
123	Takotsubo Cardiomyopathy in a Patient with Previously Undiagnosed Hypertrophic Cardiomyopathy with Latent Obstruction. Internal Medicine, 2018, 57, 2969-2973.	0.7	8
124	An angiotensin II type 1 receptor binding molecule has a critical role in hypertension in a chronic kidney disease model. Kidney International, 2017, 91, 1115-1125.	5.2	30
125	Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure. Clinical and Experimental Nephrology, 2017, 21, 858-865.	1.6	20
126	Significance of change in serum bilirubin in predicting left ventricular reverse remodeling and outcomes in heart failure patients with cardiac resynchronization therapy. Journal of Cardiology, 2017, 70, 416-419.	1.9	8

#	Article	IF	CITATIONS
127	Within-visit blood pressure variability and cardiovascular risk factors in hypertensive patients with non-dialysis chronic kidney disease. Clinical and Experimental Hypertension, 2017, 39, 665-671.	1.3	5
128	Adipocyteâ€Specific Enhancement of Angiotensin II Type 1 Receptorâ€Associated Protein Ameliorates Dietâ€Induced Visceral Obesity and Insulin Resistance. Journal of the American Heart Association, 2017, 6,	3.7	32
129	Prediction of functional recovery after percutaneous coronary revascularization for chronic total occlusion using late gadolinium enhanced magnetic resonance imaging. Journal of Cardiology, 2017, 69, 836-842.	1.9	16
130	Left main trunk stenting in a case of acute aortic dissection: a case report. Clinical Case Reports (discontinued), 2017, 5, 1649-1653.	0.5	4
131	Enhancement of intrarenal plasma membrane calcium pump isoform 1 expression in chronic angiotensin II-infused mice. Physiological Reports, 2017, 5, e13316.	1.7	2
132	Angiotensin II Type 1 Receptorâ€Associated Protein Regulates Kidney Aging and Lifespan Independent of Angiotensin. Journal of the American Heart Association, 2017, 6, .	3.7	30
133	Impact of flow-mediated dilatation and coronary calcification in providing complementary information on the severity of coronary artery disease. Atherosclerosis, 2017, 267, 146-152.	0.8	6
134	Evaluation of the Effectiveness of Xanthine Oxidoreductase Inhibitors on Haemodialysis Patients using a Marginal Structural Model. Scientific Reports, 2017, 7, 14004.	3.3	9
135	Possible impact of electronegative LDL on atherosclerosis in type 2 diabetes. Atherosclerosis, 2017, 265, 253-255.	0.8	2
136	Eplerenone-Resistant Salt-Sensitive Hypertension in Nedd4-2 C2 KO Mice. International Journal of Molecular Sciences, 2017, 18, 1250.	4.1	11
137	An Isoform of Nedd4-2 Plays a Pivotal Role in Electrophysiological Cardiac Abnormalities. International Journal of Molecular Sciences, 2017, 18, 1268.	4.1	12
138	ATRAP Expression in Brown Adipose Tissue Does Not Influence the Development of Diet-Induced Metabolic Disorders in Mice. International Journal of Molecular Sciences, 2017, 18, 676.	4.1	8
139	SP079THE CRITICAL ROLE OF ANGIOTENSIN RECEPTORâ€ASSOCIATED PROTEIN IN SALTâ€SENSITIVE HYPERTENSION. Nephrology Dialysis Transplantation, 2016, 31, i111-i112.	0.7	0
140	Effect of single-pill irbesartan/amlodipine combination-based therapy on clinic and home blood pressure profiles in hypertension with chronic kidney diseases. Clinical and Experimental Hypertension, 2016, 38, 744-750.	1.3	7
141	Comparison of direct renin inhibitor and angiotensin II receptor blocker on clinic and ambulatory blood pressure profiles in hypertension with chronic kidney disease. Clinical and Experimental Hypertension, 2016, 38, 738-743.	1.3	6
142	The lesson of ankle-brachial index for long-term clinical outcomes: Time is not a line, but a series of now-points. Atherosclerosis, 2016, 250, 186-188.	0.8	2
143	Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes. Hypertension Research, 2016, 39, 396-398.	2.7	13
144	Potential beneficial impact of angiotensin receptor blockers on arterial stiffness in hypertension. Journal of Thoracic Disease, 2016, 8, E564-E566.	1.4	0

#	Article	IF	CITATIONS
145	Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia. Lipids in Health and Disease, 2015, 14, 161.	3.0	9
146	Absence of Activation-induced Cytidine Deaminase, a Regulator of Class Switch Recombination and Hypermutation in B Cells, Suppresses Aorta Allograft Vasculopathy in Mice. Transplantation, 2015, 99, 1598-1605.	1.0	4
147	Renal Tubule Angiotensin II Type 1 Receptor–Associated Protein Promotes Natriuresis and Inhibits Saltâ€Sensitive Blood Pressure Elevation. Journal of the American Heart Association, 2015, 4, e001594.	3.7	17
148	Effects of the oriental herbal medicine Bofu-tsusho-san in obesity hypertension: A multicenter, randomized, parallel-group controlled trial (ATH-D-14-01021.R2). Atherosclerosis, 2015, 240, 297-304.	0.8	45
149	Possible therapeutic impact of the iron chelation on renal fibrosis. Hypertension Research, 2015, 38, 455-456.	2.7	3
150	Angiotensin II Type 1 Receptor Binding Molecule ATRAP as a Possible Modulator of Renal Sodium Handling and Blood Pressure in Pathophysiology. Current Medicinal Chemistry, 2015, 22, 3210-3216.	2.4	16
151	Effects of Ang II Receptor Blocker Irbesartan on Adipose Tissue Function in Mice with Metabolic Disorders. International Journal of Medical Sciences, 2014, 11, 646-651.	2.5	11
152	Deletion of the angiotensin II type 1 receptor–associated protein enhances renal sodium reabsorption and exacerbates angiotensin II–mediated hypertension. Kidney International, 2014, 86, 570-581.	5.2	47
153	Fetal programming by high-sucrose diet during pregnancy affects the vascular angiotensin II receptor–PKC–L-type Ca2+ channels (Cav1.2) axis to enhance pressor responses. Hypertension Research, 2014, 37, 796-798.	2.7	4
154	Effects of Single Pill-Based Combination Therapy of Amlodipine and Atorvastatin on Within-Visit Blood Pressure Variability and Parameters of Renal and Vascular Function in Hypertensive Patients with Chronic Kidney Disease. BioMed Research International, 2014, 2014, 1-7.	1.9	11
155	Effects of the Angiotensin Receptor Blocker Olmesartan on Adipocyte Hypertrophy and Function in Mice with Metabolic Disorders. BioMed Research International, 2014, 2014, 1-10.	1.9	13
156	Species differences in sinusoidal and canalicular efflux transport of mycophenolic acid 7―O― glucuronide in sandwichâ€cultured hepatocytes. Pharmacology Research and Perspectives, 2014, 2, e00035.	2.4	8
157	Endovascular treatment of renal artery stenosis improves contralateral renal hypertrophy with nephrotic syndrome. CEN Case Reports, 2014, 3, 53-55.	0.9	4
158	Gastrin-Releasing Peptide Contributes to the Regulation of Adult Hippocampal Neurogenesis and Neuronal Development. Stem Cells, 2014, 32, 2454-2466.	3.2	16
159	Optimized Methods for Targeted Peptide-Based Quantification of Human Uridine 5′-Diphosphate-Glucuronosyltransferases in Biological Specimens Using Liquid Chromatography–Tandem Mass Spectrometry. Drug Metabolism and Disposition, 2014, 42, 885-889.	3.3	97
160	The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertension Research, 2014, 37, 253-253.	2.7	962
161	Activation of angiotensin II type 1 receptor-associated protein exerts an inhibitory effect on vascular hypertrophy and oxidative stress in angiotensin II-mediated hypertension. Cardiovascular Research, 2013, 100, 511-519.	3.8	54
162	The immature dentate gyrus represents a shared phenotype of mouse models of epilepsy and psychiatric disease. Bipolar Disorders, 2013, 15, 405-421.	1.9	57

#	Article	IF	CITATIONS
163	Involvement of the apelin receptor <scp>APJ</scp> in Fasâ€induced liver injury. Liver International, 2013, 33, 118-126.	3.9	25
164	L/N-Type Calcium Channel Blocker Cilnidipine Added to Renin-Angiotensin Inhibition Improves Ambulatory Blood Pressure Profile and Suppresses Cardiac Hypertrophy in Hypertension with Chronic Kidney Disease. International Journal of Molecular Sciences, 2013, 14, 16866-16881.	4.1	14
165	Addition of Aliskiren to Angiotensin Receptor Blocker Improves Ambulatory Blood Pressure Profile and Cardiorenal Function Better than Addition of Benazepril in Chronic Kidney Disease. International Journal of Molecular Sciences, 2013, 14, 15361-15375.	4.1	5
166	Angiotensin Receptor–Binding Protein ATRAP/ <i>Agtrap</i> Inhibits Metabolic Dysfunction With Visceral Obesity. Journal of the American Heart Association, 2013, 2, e000312.	3.7	33
167	Enhanced Angiotensin Receptor-Associated Protein in Renal Tubule Suppresses Angiotensin-Dependent Hypertension. Hypertension, 2013, 61, 1203-1210.	2.7	45
168	Therapeutic Potential of Lowâ€Đensity Lipoprotein Apheresis in the Management of Peripheral Artery Disease in Patients With Chronic Kidney Disease. Therapeutic Apheresis and Dialysis, 2013, 17, 185-192.	0.9	27
169	Upstream Stimulatory Factors 1 and 2 Mediate the Transcription of Angiotensin II Binding and Inhibitory Protein. Journal of Biological Chemistry, 2013, 288, 19238-19249.	3.4	14
170	The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease. Hypertension Research, 2013, 36, 262-269.	2.7	24
171	What can we expect from the binding characteristics of azilsartan, a newly available angiotensin II blocker, in hypertension?. Hypertension Research, 2013, 36, 107-108.	2.7	2
172	Rituximab Treatment for Adult Purpura Nephritis with Nephrotic Syndrome. Internal Medicine, 2013, 52, 1079-1083.	0.7	17
173	Bofu-Tsu-Shosan, an Oriental Herbal Medicine, Exerts a Combinatorial Favorable Metabolic Modulation Including Antihypertensive Effect on a Mouse Model of Human Metabolic Disorders with Visceral Obesity. PLoS ONE, 2013, 8, e75560.	2.5	28
174	The Physiology and Pathophysiology of a Novel Angiotensin Receptor-binding Protein ATRAP/Agtrap. Current Pharmaceutical Design, 2013, 19, 3043-3048.	1.9	30
175	Combination Therapy of Angiotensin II Receptor Blocker and Calcium Channel Blocker Exerts Pleiotropic Therapeutic Effects in Addition to Blood Pressure Lowering: Amlodipine and Candesartan Trial in Yokohama (ACTY). Clinical and Experimental Hypertension, 2012, 34, 249-257.	1.3	6
176	Relationship of Ambulatory Blood Pressure and the Heart Rate Profile with Renal Function Parameters in Hypertensive Patients with Chronic Kidney Disease. Clinical and Experimental Hypertension, 2012, 34, 264-269.	1.3	10
177	Questionable link between normo- to microalbuminuria and home-measured blood pressure variability in hypertension. Hypertension Research, 2012, 35, 802-804.	2.7	1
178	An increase in perfusion pressure and activation of the renin–angiotensin system in the pathogenesis of hypertension and injury: strain vessels and the cerebrovascular-renal connection. Hypertension Research, 2012, 35, 972-974.	2.7	2
179	A quantitative approach to hepatic clearance prediction of metabolism by aldehyde oxidase using custom pooled hepatocytes. Xenobiotica, 2012, 42, 863-871.	1.1	31
180	Agonist-Independent Constitutive Activity of Angiotensin II Receptor Promotes Cardiac Remodeling in Mice. Hypertension, 2012, 59, 627-633.	2.7	31

#	Article	IF	CITATIONS
181	Effects of Aliskirenâ€Based Therapy on Ambulatory Blood Pressure Profile, Central Hemodynamics, and Arterial Stiffness in Nondiabetic Mild to Moderate Hypertensive Patients. Journal of Clinical Hypertension, 2012, 14, 522-529.	2.0	15
182	SREB2/GPR85, a schizophrenia risk factor, negatively regulates hippocampal adult neurogenesis and neurogenesisâ€dependent learning and memory. European Journal of Neuroscience, 2012, 36, 2597-2608.	2.6	47
183	Adult Neurogenesis Transiently Generates Oxidative Stress. PLoS ONE, 2012, 7, e35264.	2.5	101
184	Prepubertal angiotensin blockade exerts long-term therapeutic effect through sustained ATRAP activation in salt-sensitive hypertensive rats. Journal of Hypertension, 2011, 29, 1919-1929.	0.5	21
185	Effects of Multiple Factorial Intervention on Ambulatory BP Profile and Renal Function in Hypertensive Type 2 Diabetic Patients with Overt Nephropathy – A Pilot Study. Clinical and Experimental Hypertension, 2011, 33, 255-263.	1.3	12
186	Day-by-day home-measured blood pressure variability: another important factor in hypertension with diabetic nephropathy?. Hypertension Research, 2011, 34, 1249-1250.	2.7	12
187	Involvement of Runx3 in the basal transcriptional activation of the mouse angiotensin II type 1 receptor-associated protein gene. Physiological Genomics, 2011, 43, 884-894.	2.3	13
188	Emerging concept of anti-hypertensive therapy based on ambulatory blood pressure profile in chronic kidney disease. American Journal of Cardiovascular Disease, 2011, 1, 236-43.	0.5	13
189	Mechanism Analysis of Long-Term Graft Survival by Monocarboxylate Transporter-1 Inhibition. Transplantation, 2010, 90, 1299-1306.	1.0	3
190	Cardiac-Specific Activation of Angiotensin II Type 1 Receptor–Associated Protein Completely Suppresses Cardiac Hypertrophy in Chronic Angiotensin Il–Infused Mice. Hypertension, 2010, 55, 1157-1164.	2.7	60
191	Intrarenal suppression of angiotensin II type 1 receptor binding molecule in angiotensin II-infused mice. American Journal of Physiology - Renal Physiology, 2010, 299, F991-F1003.	2.7	36
192	Sustained Inhibition of Oxidized Low-Density Lipoprotein Is Involved in the Long-Term Therapeutic Effects of Apheresis in Dialysis Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1058-1065.	2.4	37
193	Expression of angiotensin II type 1 receptor-interacting molecule in normal human kidney and IgA nephropathy. American Journal of Physiology - Renal Physiology, 2010, 299, F720-F731.	2.7	23
194	Urinary Oxidative Stress Markers Closely Reflect the Efficacy of Candesartan Treatment for Diabetic Nephropathy. Nephron Experimental Nephrology, 2009, 111, e20-e30.	2.2	18
195	Effects of Angiotensin II Type 1 Receptor Blocker on Blood Pressure Variability and Cardiovascular Remodeling in Hypertensive Patients on Chronic Peritoneal Dialysis. Nephron Clinical Practice, 2009, 112, c31-c40.	2.3	34
196	Identification of an Increased Short-Term Blood Pressure Variability on Ambulatory Blood Pressure Monitoring as a Coronary Risk Factor in Diabetic Hypertensives. Clinical and Experimental Hypertension, 2009, 31, 259-270.	1.3	36
197	Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy. Hypertension Research, 2009, 32, 950-955.	2.7	44
198	Blood Pressure Variability As Well As Blood Pressure Level is Important for Left Ventricular Hypertrophy and Brachial-Ankle Pulse Wave Velocity in Hypertensives. Clinical and Experimental Hypertension, 2009, 31, 669-679.	1.3	37

#	Article	IF	CITATIONS
199	A case of a duodenal gastrointestinal stromal tumor diagnosed with the aid of diffusion-weighted magnetic resonance imaging. Clinical Journal of Gastroenterology, 2009, 2, 384-387.	0.8	3
200	Enhancement of Tâ€cellâ€mediated antiâ€tumour immunity via the ectopically expressed glucocorticoidâ€induced tumour necrosis factor receptorâ€related receptor ligand (GITRL) on tumours. Immunology, 2009, 127, 489-499.	4.4	34
201	Angiotensin II type 1 receptor-associated protein prevents vascular smooth muscle cell senescence via inactivation of calcineurin/nuclear factor of activated T cells pathway. Journal of Molecular and Cellular Cardiology, 2009, 47, 798-809.	1.9	39
202	Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis. Atherosclerosis, 2009, 207, 186-190.	0.8	57
203	Beh§et's disease complicated by IgA nephropathy with nephrotic syndrome. Clinical and Experimental Nephrology, 2008, 12, 224-227.	1.6	6
204	FR255734, a Humanized, Fc-Silent, Anti-CD28 Antibody, Improves Psoriasis in the SCID Mouse-Psoriasis Xenograft Model. Journal of Investigative Dermatology, 2008, 128, 1969-1976.	0.7	33
205	Effect of Olmesartan on Tissue Expression Balance Between Angiotensin II Receptor and Its Inhibitory Binding Molecule. Hypertension, 2008, 52, 672-678.	2.7	22
206	Ambulatory Blood Pressure and Heart Rate in Hypertensives with Renal Failure: Comparison between Diabetic Nephropathy and Non-Diabetic Glomerulopathy. Clinical and Experimental Hypertension, 2008, 30, 33-43.	1.3	21
207	A Blocking Anti-CD28-Specific Antibody Induces Long-Term Heart Allograft Survival by Suppression of the PKCî,-JNK Signal Pathway. Transplantation, 2008, 85, 1051-1055.	1.0	20
208	Expression of MAK-V/Hunk in renal distal tubules and its possible involvement in proliferative suppression. American Journal of Physiology - Renal Physiology, 2007, 292, F1526-F1536.	2.7	21
209	Novel Regulatory Effect of Angiotensin II Type 1 Receptor-Interacting Molecule on Vascular Smooth Muscle Cells. Hypertension, 2007, 50, 926-932.	2.7	49
210	Immunomodulatory Properties of FK734, a Humanized Anti-CD28 Monoclonal Antibody With Agonistic and Antagonistic Activities. Transplantation, 2007, 83, 304-313.	1.0	28
211	Requirement of Apelin-Apelin Receptor System for Oxidative Stress-Linked Atherosclerosis. American Journal of Pathology, 2007, 171, 1705-1712.	3.8	121
212	A Possible Relationship of Nocturnal Blood Pressure Variability with Coronary Artery Disease in Diabetic Nephropathy. Clinical and Experimental Hypertension, 2007, 29, 31-42.	1.3	37
213	The role of angiotensin AT1 receptor-associated protein in renin-angiotensin system regulation and function. Current Hypertension Reports, 2007, 9, 121-127.	3.5	38
214	Effect of a Novel Inducible Nitric Oxide Synthase Inhibitor, FR260330, in Prevention of Renal Ischemia/Reperfusion Injury in Vervet Monkeys. Transplantation, 2006, 81, 627-631.	1.0	14
215	Chronic activation of the prostaglandin receptor EP4 promotes hyaluronan-mediated neointimal formation in the ductus arteriosus. Journal of Clinical Investigation, 2006, 116, 3026-3034.	8.2	146
216	Effect of a Novel Inducible Nitric Oxide Synthase Inhibitor in Prevention of Rat Chronic Aortic Rejections. Transplantation, 2005, 79, 1386-1392.	1.0	12

#	Article	IF	CITATIONS
217	Immunosuppression with a Combination of Pg490–88 and a Subtherapeutic Dose of FK506 in a Canine Renal Allograft Model. Transplantation, 2005, 79, 1537-1544.	1.0	13
218	Heparin recovers AT1 receptor and its intracellular signal transduction in cultured vascular smooth muscle cells. FEBS Letters, 2005, 579, 281-284.	2.8	17
219	The novel angiotensin II type 1 receptor (AT1R)-associated protein ATRAP downregulates AT1R and ameliorates cardiomyocyte hypertrophy. FEBS Letters, 2005, 579, 1579-1586.	2.8	82
220	Nuclear receptor LXRα is involved in cAMP-mediated human renin gene expression. Molecular and Cellular Endocrinology, 2004, 224, 11-20.	3.2	14
221	Acute renal failure due to cholesterol crystal embolism treated with LDL apheresis followed by corticosteroid and candesartan. Clinical and Experimental Nephrology, 2003, 7, 67-71.	1.6	26
222	Differential Induction of Protein Kinase C Isoforms at the Cardiac Hypertrophy Stage and Congestive Heart Failure Stage in Dahl Salt-Sensitive Rats. Hypertension Research, 2003, 26, 421-426.	2.7	40
223	Lipoxygenase Products Regulate Nitric Oxide and Inducible Nitric Oxide Synthase Production in Interleukin-1.BETA. Stimulated Vascular Smooth Muscle Cells Hypertension Research, 2003, 26, 177-184.	2.7	15
224	Title is missing!. Molecular and Cellular Biochemistry, 2000, 212, 203-209.	3.1	12
225	Inflammation influences vascular remodeling through AT ₂ receptor expression and signaling. Physiological Genomics, 2000, 2, 13-20.	2.3	143
226	Molecular Mechanism of Fibronectin Gene Activation by Cyclic Stretch in Vascular Smooth Muscle Cells. Journal of Biological Chemistry, 2000, 275, 34619-34627.	3.4	44
227	Interferon-Î ³ Induces AT 2 Receptor Expression in Fibroblasts by Jak/STAT Pathway and Interferon Regulatory Factor-1. Circulation Research, 2000, 86, 233-240.	4.5	33
228	Angiotensinogen Gene Polymorphism Near Transcription Start Site and Blood Pressure. Hypertension, 1999, 34, 430-434.	2.7	49
229	AT ₂ Receptor and Vascular Smooth Muscle Cell Differentiation in Vascular Development. Hypertension, 1999, 33, 1414-1419.	2.7	83
230	Stimulation of Different Subtypes of Angiotensin II Receptors, AT ₁ and AT ₂ Receptors, Regulates STAT Activation by Negative Crosstalk. Circulation Research, 1999, 84, 876-882.	4.5	104
231	Interferon Regulatory Factors Regulate Interleukin-1β–Converting Enzyme Expression and Apoptosis in Vascular Smooth Muscle Cells. Hypertension, 1999, 33, 162-166.	2.7	38
232	Cloning and Characterization of ATRAP, a Novel Protein That Interacts with the Angiotensin II Type 1 Receptor. Journal of Biological Chemistry, 1999, 274, 17058-17062.	3.4	149
233	Renin–angiotensin system and fibronectin gene expression in Dahl Iwai salt-sensitive and salt-resistant rats. Journal of Hypertension, 1999, 17, 81-89.	0.5	31
234	Tacrolimus versus cyclosporin A: a comparative study on rat renal allograft survival. Transplant International, 1999, 12, 92-99.	1.6	5

#	Article	IF	CITATIONS
235	Possible role of c-Jun in transcription of the mouse renin gene. Kidney International, 1998, 54, 382-393.	5.2	7
236	Genetic deficiency of angiotensinogen produces an impaired urine concentrating ability in mice. Kidney International, 1998, 53, 548-555.	5.2	74
237	GP130 Is Involved in Stretch-Induced MAP Kinase Activation in Cardiac Myocytes. Biochemical and Biophysical Research Communications, 1998, 245, 928-932.	2.1	19
238	Effect of Genetic Deficiency of Angiotensinogen on the Renin-Angiotensin System. Hypertension, 1998, 32, 223-227.	2.7	15
239	Endothelial Nitric Oxide Synthase Gene Polymorphism and Acute Myocardial Infarction. Hypertension, 1998, 32, 521-526.	2.7	325
240	Mechanism of Angiotensin II-mediated Regulation of Fibronectin Gene in Rat Vascular Smooth Muscle Cells. Journal of Biological Chemistry, 1998, 273, 26487-26496.	3.4	48
241	Activation of angiotensinogen gene in cardiac myocytes by angiotensin II and mechanical stretch. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1998, 275, R1-R9.	1.8	34
242	Increased Cardiac Angiotensin II Receptors in Angiotensinogen-Deficient Mice. Hypertension, 1998, 31, 45-49.	2.7	13
243	A Novel Proximal Element Mediates the Regulation of Mouse Ren-1C Promoter by Retinoblastoma Protein in Cultured Cells. Journal of Biological Chemistry, 1997, 272, 16845-16851.	3.4	8
244	Stretch-Induced Map Kinase Activation in Cardiomyocytes of Angiotensinogen-Deficient Mice. Biochemical and Biophysical Research Communications, 1997, 235, 36-41.	2.1	37
245	Relationship between hepatic angiotensinogen mRNA expression and plasma angiotensinogen in patients with chronic hepatitis. Life Sciences, 1997, 60, 1623-1633.	4.3	12
246	Distribution of $\hat{l}\pm 1B$ -adrenergic receptor mRNA expression along rat nephron segments. Kidney International, 1997, 51, 1548-1552.	5.2	3
247	Angiotensin-Converting Enzyme Gene <i>I/D</i> Polymorphism and Carotid Plaques in Japanese. Hypertension, 1997, 30, 569-573.	2.7	30
248	Angiotensin-Converting Enzyme Gene Polymorphism Adds Risk for the Severity of Coronary Atherosclerosis in Smokers. Hypertension, 1997, 30, 574-579.	2.7	26
249	Tissue Angiotensinogen Gene Expression Induced by Lipopolysaccharide in Hypertensive Rats. Hypertension, 1997, 30, 859-867.	2.7	31
250	Essential Hypertension and 5′ Upstream Core Promoter Region of Human Angiotensinogen Gene. Hypertension, 1997, 30, 1325-1330.	2.7	83
251	Effects of Slowly Performed Daytime Hemodialysis (Slow HD) on the Pharmacokinetics of Vancomycin in Hemodynamically Unstable Patients with Renal Failure. Blood Purification, 1996, 14, 20-25.	1.8	5
252	Role of Transcriptional cis -Elements, Angiotensinogen Gene–Activating Elements, of Angiotensinogen Gene in Blood Pressure Regulation. Hypertension, 1996, 27, 502-507.	2.7	48

#	Article	IF	CITATIONS
253	Tissue-Specific Regulation of Angiotensinogen Gene Expression in Spontaneously Hypertensive Rats. Hypertension, 1996, 27, 1216-1223.	2.7	59
254	Molecular Variant of Angiotensinogen Gene Is Associated With Coronary Atherosclerosis. Circulation, 1995, 91, 951-954.	1.6	93
255	Wistar Fatty Rat Is Obese and Spontaneously Hypertensive. Hypertension, 1995, 25, 146-150.	2.7	22
256	Adenosine A 1 Receptor mRNA in Microdissected Rat Nephron Segments. Hypertension, 1995, 26, 1181-1185.	2.7	44
257	Recent Advances in the Study of Renin and Angiotensinogen Genes: From Molecules to the Whole Body Hypertension Research, 1995, 18, 7-18.	2.7	40
258	DNA fingerprint analysis of Dahl-Iwai salt-sensitive rats (S) and salt-resistant rats (R). Life Sciences, 1994, 55, 701-705.	4.3	8
259	Species-Specific Expression of the Hepatic Renin Gene Journal of Veterinary Medical Science, 1994, 56, 109-114.	0.9	5
260	THE ANTILYMPHOCYTIC ACTIVITY OF BREQUINAR SODIUM AND ITS POTENTIATION BY CYTIDINE. Transplantation, 1993, 56, 374-380.	1.0	14
261	Isolation of the Mouse Ren-1C Gene and Characterization of Renin Gene Expression in Both ES-D3 Cells and Their Parental Mouse Strain Journal of Reproduction and Development, 1993, 39, 19-24.	1.4	4
262	Regulation of activin \hat{l}^2 A mRNA level by cAMP. Biochemical and Biophysical Research Communications, 1992, 182, 773-778.	2.1	18
263	Structure and Expression of the Mouse Angiotensinogen Gene International Heart Journal, 1992, 33, 113-124.	0.6	30
264	An oxidized analog of alpha-human atrial natriuretic polypeptide is a selective agonist for the atrial-natriuretic-polypeptide clearance receptor which lacks a guanylate cyclase. FEBS Journal, 1992, 203, 425-432.	0.2	15
265	Epidermal Growth Factor Prolongs Survival Time of Tumor-bearing Mice. Japanese Journal of Cancer Research, 1990, 81, 495-500.	1.7	4